Antimycobacterial activity of the antiinflammatory agent diclofenac sodium, and its synergism with streptomycin

Brazilian Journal of Microbiology

Noton K. Dutta²  Sujata G. Dastidar²  Asok Kumar²  Kaushiki Mazumdar²  Raja Ray¹  Atindra N. Chakrabarty¹ 

[1] ,Jadavpur University IDepartment of Pharmaceutical Technology Calcutta,India

关键词: antiinflammatory drug;    diclofenac sodium;    antimycobacterial activity;    streptomycin;    synergism;    non-antibiotic;    droga antiinflamatória;    diclofenac sódico;    atividade antimicobacteriana;    estreptomicina;    sinergismo;    não-antibiótico;   

DOI  :  10.1590/S1517-83822004000300009

来源: SciELO

【 摘 要 】

Diclofenac sodium, an antiinflammatory agent, exhibited remarkable inhibitory action against both drug sensitive and drug resistant clinical isolates of Mycobacterium tuberculosis, as well as other mycobacteria. This drug was tested in vitro against 45 different strains of mycobacteria, most of which were inhibited by the drug at 10-25 µg/ml concentration. When tested in vivo, diclofenac, injected at 10 µg/g body weight of a Swiss strain of white mice, could significantly protect them when challenged with 50 median lethal dose of M. tuberculosis H37 Rv 102. According to chi2 test, the in vivo data were highly significant (p<0.01). Diclofenac was further tested for synergism with the conventional antimycobacterial drug streptomycin against M. smegmatis 798. When compared with their individual effects, synergism was found to be statistically significant (p<0.05). By the checkerboard assessment procedure, the fractional inhibitory concentration index of this combination was found to be 0.37, confirming synergism.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License